A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

NCT05940532 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Sugemalimab and Chemotherapy

Sponsor

Hunan Cancer Hospital